Incidence of Endophthalmitis after Intravitreal Injections: Risk Factors, Microbiology Profile, and Clinical Outcomes

REFERENCES

• CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20)1897–1908. doi:10.1056/NEJMoa1102673.
   PubMed Web of Science ®Google Scholar
• Ross EL, Hutton DW, Stein JD. et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016;134(8):888–896. doi:10.1001/jamaophthalmol.2016.1669.
   PubMed Web of Science ®Google Scholar
• Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. ClinOphthalmol. 2009;3:41–47. doi:10.2147/OPTH.S4477.
   Google Scholar
• Lattanzio R, Cicinelli MV, Bandello F. Intravitreal steroids in diabetic macular edema. DevOphthalmol. 2017;60:78–90. doi:10.1159/000459691.
   Google Scholar
• Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections n an operating room setting. Retina. 2014;34(5):951–957. doi:10.1097/IAE.0000000000000071.
   PubMed Web of Science ®Google Scholar
• Fileta JB, Scott IU, Flynn HW. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143–149. doi:10.3928/23258160-20140306-08.
   PubMed Web of Science ®Google Scholar
• Englander M, Chen TC, Paschalis EI, Miller JW, Kim IK. Intravitreal injections at the massachusetts eye and ear infirmary: analysis of treatment indications and postinjectionendophthalmitis rates. Br J Ophthalmol. 2013;97(4):460–465. doi:10.1136/bjophthalmol-2012-302435.
   PubMed Web of Science ®Google Scholar
• Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS, Creuzot-Garcher C. FRCR net (FRenCh Retina specialists net). endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160(1):17–25.e1. doi:10.1016/j.ajo.2015.04.013.
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661. doi:10.1097/IAE.0b013e31820a67e4.
   PubMed Web of Science ®Google Scholar
• Storey P, Dollin M, Pitcher J. et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283–289. doi:10.1016/j.ophtha.2013.08.037.
   PubMed Web of Science ®Google Scholar
• Rayess N, Rahimy E, Storey P. et al. PostinjectionEndophthalmitis rates and characteristics following intravitrealbevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93. doi:10.1016/j.ajo.2016.02.028.
   PubMed Web of Science ®Google Scholar
• A L L, Wykoff CC, Wang R. et al. Endophthalmitis after intravitreal injection role of prophylactic topical ophthalmic antibiotic. Retina. 2016;36(7):1349–1356. doi:10.1097/IAE.0000000000000901.
   PubMed Web of Science ®Google Scholar
• Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–1614. doi:10.1016/j.ophtha.2012.02.014.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Narayanan R, Gupta V, Rosenfeld PJ, Martin DF, Chakravarthy U. Counterfeit avastin in india: punish the criminals, not the patients. Am J Ophthalmol. 2016;170:228–231. doi:10.1016/j.ajo.2016.05.023.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Brucker AJ, Chang S. et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5 Suppl):S3–19.
   PubMed Web of Science ®Google Scholar
• Frenkel REP, Haji SA, La M, Frenkel MP, Reyes A. A protocol for the retina surgeon’s safe initial intravitreal injections. ClinOphthalmol. 2010;4:1279–1285. doi:10.2147/OPTH.S12846.
   Google Scholar
• Schwartz SG, Flynn HW. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injections. CurrOphthalmol Rep. 2014;2(1):1–5. doi:10.1007/s40135-013-0033-1.
   PubMedGoogle Scholar
• Lyall DAM, Tey A, Foot B. et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26(12):1517–1526. doi:10.1038/eye.2012.199.
   PubMed Web of Science ®Google Scholar
• Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96(12):1474–1478. doi:10.1136/bjophthalmol-2012-302030.
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn’t blind people, people blind people. Am J Ophthalmol. 2012;153(2):196–203.e1. doi:10.1016/j.ajo.2011.11.023.
   PubMed Web of Science ®Google Scholar
• Jones DM, Liesegang TJ, Robinson NM. Laboratory diagnosis of ocular infections. In: Cumulative Techniques and Procedures in Clinical Microbiology (Cumitech 13). Washington, DC: American Society of Microbiology; 1981.
   Google Scholar
• Kumar A, Ravani R. Using intravitrealbevacizumab (Avastin)- Indian Scenariao. Indian J Ophthalmol. 2017;65(7):545–548. doi:10.4103/ijo.IJO_431_17.
   PubMed Web of Science ®Google Scholar
• Woo SJ, Han JM, Ahn J. et al. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina. 2012;32(4):667–671. doi:10.1097/IAE.0b013e31822c296b.
   PubMed Web of Science ®Google Scholar
• Woo SJ, Ahn J, Park KU, Park KH. Reply: to PMID 22307220. Retina. 2013;33(3):670–671. doi:10.1097/IAE.0b013e31826d3534.
   PubMed Web of Science ®Google Scholar
• Ripoll Gallardo A, Meneghetti G, Ragazzoni L. et al. Multiple withdrawals from single-use vials: a study on sterility. Int J Pharm. 2015;485(1–2):160–163. doi:10.1016/j.ijpharm.2015.03.010.
   PubMed Web of Science ®Google Scholar
• Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch ClinExpOphthalmol. 2013;251(8):1885–1890. doi:10.1007/s00417-013-2274-y.
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015; Nov 122(11):2311–2315.e1. doi:10.1016/j.ophtha.2015.07.005.
   PubMed Web of Science ®Google Scholar
• Friedman DA, Mason JO, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975–981. doi:10.1097/IAE.0b013e3182877585.
   PubMed Web of Science ®Google Scholar
• Casparis H, Wolfensberger TJ, Becker M. et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12–17. doi:10.1097/IAE.0b013e31829f74b0.
   PubMed Web of Science ®Google Scholar
• Sigford DK, Reddy S, Mollineaux C, Schaal S. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. ClinOphthalmol. 2015;9:773–781. doi:10.2147/OPTH.S77067.
   Web of Science ®Google Scholar
• Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina. 2011;31(10):2032–2036. doi:10.1097/IAE.0b013e31820f4b4f.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Chomsky AS, Sternberg P. Reducing the risk of endophthalmitis after intravitreous injection. JAMA Ophthalmol. 2013;131(5):674–675. doi:10.1001/jamaophthalmol.2013.2914.
   PubMed Web of Science ®Google Scholar
• Meredith TA, McCannel CA, Barr C. et al. Postinjectionendophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2015;122(4):817–821. doi:10.1016/j.ophtha.2014.10.027.
   PubMed Web of Science ®Google Scholar
• Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino De Kaspar H. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina. 2014;34(5):943–950. doi:10.1097/IAE.0000000000000011.
   PubMed Web of Science ®Google Scholar
• Tabandeh H, Boscia F, Sborgia A. et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014;34(1):18–23. doi:10.1097/IAE.0000000000000008.
   PubMed Web of Science ®Google Scholar
• Shah CP, Garg SJ, Vander JF. et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028–2034. doi:10.1016/j.ophtha.2011.02.034.
   PubMed Web of Science ®Google Scholar
• Garg SJ, Dollin M, Hsu J, Storey P, Vander JF. Effect of a Strict “No-Talking” Policy during Intravitreal Injection on Post-Injection Endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2015;46(10):1028–1034. doi:10.3928/23258160-20151027-07.
   PubMed Web of Science ®Google Scholar
• Moloney TP, Patk J. Microbiological isolates and antibiotic sensitivities in culture-proven endophthalmitis: a 15-year review. Br J Ophthalmol. 2014;98(11):1492–1497. doi:10.1136/bjophthalmol-2014-305030.
   PubMed Web of Science ®Google Scholar